Search Results for “Novartis” – Page 27 – media

GlaxoSmithKline chief Emma Walmsley nets $6.8M in pay in her first year at the helm

Investors who pressed GlaxoSmithKline to slash new CEO Emma Walmsley’s pay package before she took the helm probably won’t much like her overall compensation figure for 2017.
- Source: fiercepharma
- 554
- March 16, 2018
Company Insight GSK
Bay Area’s Rani Therapeutics Lands $53M as Company Moves to Clinical Trials

Rani Therapeutics scored $53 million in financing to take its oral pill designed to replace injectable drug delivery for chronic disease treatment into clinical trials.
- Source: Biospace
- 473
- February 28, 2018
chronic diseases Company Insight oral pill
Merck’s ERK inhibitor shows promise in combo against resistant cancers

One-fifth of patients in a phase 1 study responded to an investigational ERK inhibitor from Merck, bolstering hopes that this type of drug could be used effectively in combination with other cancer drugs. ERK is a cell signal that is believed to drive the growth of many cancers.
- Source: fiercebiotech
- 547
- February 23, 2018
cancer drugs Company Insight inhibitor
Global Investors Back Rani Therapeutics With $53 Million As Company Moves To Clinical Trials

Rani Therapeutics, the developer of a pill designed to replace injectable drug delivery for patients suffering from chronic diseases, today announced that it has raised $53 million to invest in manufacturing in preparation for human clinical trials. This investment brings the total raised to $142 million in funding.
- Source: Prnewswire;
- 517
- February 13, 2018
chronic diseases Clinical Trials Series
Another Day, Another Breakthrough Tag for GlaxoSmithKline’s Bexsero

GlaxoSmithKline’s meningitis B vaccine Bexsero is in a class all by itself when it comes to snagging the Breakthrough Therapy Designation from the U.S. Food and Drug Administration(FDA).
- Source: biospace
- 585
- February 9, 2018
Bexsero FDA GSK meningitis B vaccine
NICE becomes latest champion for digital health

NICE has become the latest organisation to champion digital health, recommending that the NHS should trial an online and mobile programme to treat depression.
- Source: Pharma Phorum
- 745
- February 1, 2018
Company Insight digital health EHR NICE
BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing

BridgeBio Pharma today announced that it is has licensed infigratinib (BGJ398), a highly potent and selective inhibitor of the tyrosine kinase receptor FGFR, from Novartis. In addition, BridgeBio announced that it was launching new subsidiary QED Therapeutics to drive development of infigratinib with an initial financial commitment of $65 million.
- Source: Prnewswire
- 606
- February 1, 2018
achondroplasia infigratinib (BGJ398) Market Views Novartis QED Therapeutics
Berkshire Hathaway, Amazon, chase partner to create healthcare company

It’s no secret Jeff Bezos has been looking to crack healthcare. But no one expected him to pull in Warren Buffett and Jamie Dimon, too.
- Source: Digital Insurance
- 433
- January 31, 2018
Company Insight healthcare
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

Novartis AG (NYSE: NVS) today announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approval of its new drug application (NDA) for Lutathera® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors, in adults.
- Source: Novartis
- 491
- January 29, 2018
FDA GEP-NETs Lutathera® New Approvals
Researchers describe receiver-free, glucose-sensing contact lens

A team of South Korean researchers is the latest to tout a smart, glucose-sensing contact lens. In a research article published today in Science Advances, the team described soft lenses carrying a tiny LED light that automatically turns off in the event of high glucose levels, as well as their efforts to test the lens in vivo.
- Source: MobiHealthNews
- 564
- January 26, 2018
blood glucose levels glycemic Researches wearables

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.